United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News FDA sets review date for Ironshore Pharmaceuticals’ ADHD drug HLD200 Ironshore Pharmaceuticals & Development, a subsidiary of Highland Therapeutics, has reached a significant milestone with the U.S. Food… bypharmanewsdailyJuly 15, 2018
